Recurrent Implantation Failure: Evidence-Based Evaluation After Unsuccessful IVF Transfers

Navigating multiple unsuccessful in vitro fertilization (IVF) cycles represents one of the most emotionally challenging and clinically complex scenarios in reproductive medicine. When embryos fail to implant, patients are frequently exposed to a wide array of non-standardized diagnostic tests, conflicting definitions, and unproven add-on therapies.

To achieve diagnostic clarity, clinical management must be anchored in rigorous science while maintaining a patient-centered approach. This guide outlines established diagnostic frameworks for evaluating recurrent implantation issues, distinguishing validated clinical workups from investigational hypotheses, and translating physiological mechanisms into an individualized care strategy for patients seeking advanced reproductive care in Dubai.

Defining Implantation Failure: Modern Consensus vs. Fixed Metrics

There is no single, universally accepted numerical definition of recurrent implantation failure (RIF). Historically, clinical literature defined RIF as the failure to achieve a clinical pregnancy after three or more failed IVF cycles or the transfer of four or more cleavage-stage embryos (or two or more morphologically high-quality blastocysts).

Modern reproductive endocrinology—guided by consensus updates from the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM)—increasingly shifts away from rigid numerical cutoffs. Current guidance supports an individualized assessment based on the predicted cumulative chance of implantation, embryo developmental stage and morphological grading, maternal age, and whether embryo ploidy has been evaluated.

Core Domains of Recurrent Implantation Evaluation

Biologically, successful implantation depends on precise temporal synchrony between three core physiological components:

• Embryonic Competence: The developmental and chromosomal integrity of the blastocyst.
• Endometrial Receptivity: A functional, structurally sound, and temporally aligned uterine lining.
• Maternal-Fetal Interface: A balanced endocrine and local micro-environmental state that permits initial trophoblast attachment.

Current scientific evidence indicates that embryonic aneuploidy—primarily associated with maternal age-related meiotic variations—remains a primary factor in implantation failure. Clinicians exercise diagnostic discipline by evaluating isolated abnormal values in single surrogate markers (such as Anti-Müllerian Hormone [AMH] levels or minor anatomical variants) within a broader multi-factorial context rather than as standalone causes of implantation failure.

Phase 1 Diagnostic Workup: Evaluating Embryonic Competence and Genetic Factors

The initial diagnostic phase focuses on determining whether repeated implantation failure may be driven by intrinsic embryonic factors, particularly numerical chromosomal variations (aneuploidy) or structural parental genetic rearrangements.

Chromosomal Evaluation via PGT-A

Preimplantation Genetic Testing for Aneuploidies (PGT-A) via next-generation sequencing (NGS) combined with SNPs analysis evaluates whole-chromosome copy numbers and embryo ploidy prior to transfer. Morphologically high-grade blastocysts can still harbor numerical chromosomal variations that halt development at or shortly after initial attachment.

While PGT-A may clarify the contribution of embryo ploidy and reduce the number of unproductive transfers, patients should understand that PGT-A does not repair an embryo, alter its intrinsic developmental viability, or guarantee a live birth. Its application should be considered in selected cases as part of shared clinical decision-making.

Paternal Factors & Sperm DNA Integrity Testing

Standard semen analysis evaluates concentration, motility, and basic morphology, but does not assess nuclear DNA integrity. High levels of Sperm DNA Fragmentation (SDF) have been investigated for potential late paternal effects during embryo development.

However, routine SDF testing is not recommended for all cases of implantation failure according to international guidelines. It may be discussed in selected clinical scenarios where separate male-factor indications exist or where the pattern of embryo development raises suspicion of a paternal contribution. Although no embryological pattern is specific for sperm DNA fragmentation, relatively normal fertilisation and early cleavage followed by delayed development, impaired progression to the blastocyst stage or recurrent post-cleavage embryo arrest may provide a clinical clue, particularly when the pattern is reproducible across cycles. This highlights the importance of close collaboration between the clinician and embryologist: assessment of male-factor contribution should incorporate not only conventional semen parameters but also fertilisation, cleavage dynamics, blastulation and the overall pattern of embryo development observed in the laboratory.

Diagnostic Evaluation Tools for Embryonic Competence

Phase 2 Diagnostic Workup: Evaluating Uterine Cavity Architecture and the Local Microenvironment

Evaluating the uterine cavity requires careful assessment of structural architecture and micro-environmental health to ensure no mechanical or localized barriers interfere with embryo apposition.

Evidence Reasoning Framework for Uterine Interventions

Consensus-Backed & Selected Clinical Interventions:

• Surgical correction of documented intra-cavitary anatomical lesions (e.g., polyps, submucosal fibroids, uterine septa).
• Assessment and surgical management of hydrosalpinx prior to embryo transfer.
• Evaluation for chronic endometritis (CD138⁺) in selected persistent cases.
• Targeted endometrial injury (scratching) strictly evaluated for selected RIF patients demonstrating immune under-activation, moving away from routine, unselected usage.

Investigational / Not Routinely Recommended Interventions:

• Routine mechanical endometrial scratching in unselected patient populations (e.g., first-time IVF transfers).
• Intrauterine Platelet-Rich Plasma (PRP) or Granulocyte Colony-Stimulating Factor (G-CSF) instillations.
• Empirical immunomodulatory infusions (e.g., intralipids, high-dose systemic steroids, IVIG).
• Routine inherited thrombophilia panels in isolated implantation failure.

Anatomical Cavity Evaluation

Intra-cavitary structural lesions—such as congenital uterine septa, submucosal leiomyomas, endometrial polyps, and intrauterine adhesions (Asherman syndrome)—can disrupt mechanical contact and local blood supply. High-resolution three-dimensional transvaginal ultrasonography (3D TVUS) serves as an effective initial non-invasive tool. Diagnostic hysteroscopy is not routinely indicated for every patient but may be considered when intra-cavitary anomalies or adhesions are suspected on non-invasive imaging. In patients with RIF, diagnostic hysteroscopy may be considered even in the absence of suspected abnormalities on ultrasound and may be combined with an endometrial biopsy to assess for chronic endometritis.

Chronic Endometritis (CE) & Microenvironment Factors

Chronic endometritis is a localized inflammation of the endometrial stroma characterized by plasma cell infiltration, typically identified histologically via CD138⁺ immunohistochemical staining. While targeted antibiotic therapy may be considered following positive diagnostic confirmation, routine screening across all IVF populations remains a subject of ongoing clinical study rather than a mandatory universal protocol.

Endometriosis and Adenomyosis Considerations

Pelvic endometriosis and adenomyosis can alter local peritoneal and endometrial environments. For patients with documented or suspected endometriosis or adenomyosis, pre-transfer medical suppression (such as extended GnRH agonist pre-treatment) may be discussed in selected cases. However, available evidence regarding its direct impact on overall live birth rates remains inconclusive; therefore, pre-treatment suppression should be individualized rather than applied as a universal protocol.

Endometrial Immune Profiling

ESHRE does not currently recommend the routine use of commercially available tests of endometrial receptivity in recurrent implantation failure. However, the guideline acknowledges that assessment of specific aspects of endometrial function by testing can be considered.

One particularly relevant area is endometrial immune profiling. Rather than assuming that implantation failure is associated with excessive immune activity, this approach assesses the local immune environment during the implantation window and distinguishes between immune over-activation, under-activation, mixed profiles, and apparently balanced immune activity.

In a large prospective cohort reported by Lédée et al., endometrial immune profiling among 1,738 infertile patients demonstrated that approximately 45% presented with immune over-activation, 28% with under-activation, 10% with a mixed profile, and 17% with no identified immune dysregulation.

This biological heterogeneity offers an explanation for the inconsistent results of empirical immunological treatments in IVF. For example, recent critical reviews (Shoham et al., 2026) emphasize that applying interventions indiscriminately often leads to null results. If patients with an under-activated immune profile (who might benefit from local pro-inflammatory stimulation like targeted endometrial scratching or hCG supplementation) receive immunosuppressive therapies (like corticosteroids or intralipids), the treatment could be counterproductive.

At present, endometrial immune profiling remains investigational and is not recommended for routine care. Nevertheless, in selected patients with recurrent implantation failure, it represents a necessary shift from unvalidated empirical add-ons toward a biomarker-guided, biologically informed approach: first identifying the direction of the local immune dysregulation, and only then tailoring the intervention.

Phase 3 Diagnostic Workup: Systemic, Endocrine, and Metabolic Evaluation

Systemic maternal factors can influence endometrial responsiveness and endocrine support during the early peri-implantation phase.

Endocrine Optimization

Systemic endocrine parameters should be assessed and optimized prior to frozen embryo transfer (FET) cycles:

• Thyroid Function: Thyroid function should be evaluated, and clinically relevant thyroid dysfunction managed according to established fertility and endocrine guidelines.
• Metabolic & Prolactin Markers: Unmanaged hyperprolactinemia or significant metabolic dysfunction (such as elevated glycated hemoglobin [HbA1c] or insulin resistance) should be addressed to support optimal physiological conditions prior to transfer.

Antiphospholipid Syndrome (APS) vs. Inherited Thrombophilia

• Acquired Antiphospholipid Syndrome (APS): Testing for acquired antiphospholipid antibodies (anticardiolipin, anti-β₂-glycoprotein I, and lupus anticoagulant) is primarily relevant when additional clinical risk factors, such as recurrent pregnancy loss or prior thromboembolic events, are present. Formal diagnosis requires meeting specific clinical and laboratory criteria.
• Inherited Thrombophilia Panels: Routine screening for inherited thrombophilias (such as Factor V Leiden, Prothrombin gene variants, or MTHFR mutations) in patients with isolated implantation failure without personal or familial thromboembolic history is not recommended by major international guidelines, as clear evidence linking these variants to pure implantation failure is lacking.

Structured, Individualized Assessment After Unsuccessful Embryo Transfers

To ensure systematic evaluation and avoid unproven or redundant testing, clinical assessment follows a structured pathway tailored to individual patient history:

1. Review Prior IVF Records: Re-evaluate the number of transfers, developmental stages of transferred embryos, morphological grading, day of transfer, cycle type (natural vs. medicated or ovulation induction), endometrial thickness, ease of transfer, and overall implantation history.
2. Reassess Uterine and Tubal Factors: Utilize high-resolution 3D ultrasound to evaluate cavity architecture and rule out hydrosalpinges. Consider diagnostic hysteroscopy if imaging suggests intra-cavitary pathology or adhesions.
3. Consider Gamete and Parental Genetic Factors: Evaluate whether PGT-A or parental karyotyping is clinically indicated based on individual reproductive history and previous cycle outcomes.
4. Assess Relevant Medical & Endocrine Factors: Check thyroid parameters, prolactin, and metabolic status. Evaluate for antiphospholipid antibodies if additional obstetric or thrombotic risk factors exist.
5. Discuss Selected Non-Routine Investigations: Evaluate chronic endometritis or endometrial immune parameters only after discussing the limitations and current state of clinical evidence.
6. Avoid Unproven Add-Ons: Refrain from routine empirical immunomodulatory treatments or unvalidated uterine instillations outside of targeted clinical indications or approved clinical trials.

Frequently Asked Questions

When should additional investigations be considered after failed embryo transfers?

Formal clinical re-evaluation is generally recommended after two or more unsuccessful transfers of morphologically high-quality embryos, or when cumulative predicted implantation chances suggest a detailed review is warranted. The timing depends on maternal age, embryo quality, ploidy status, and individual clinical history.

Does a euploid embryo guarantee implantation?

No diagnostic test or screening method can guarantee implantation or a live birth. While PGT-A confirms whole-chromosome normality (euploidy), successful implantation also depends on uterine anatomical health, endometrial receptivity, temporal synchrony, and underlying systemic factors.

Is routine endometrial scratching recommended after multiple failed transfers?

Current high-quality clinical evidence strongly advises against the routine use of mechanical endometrial scratching for unselected patients undergoing IVF (e.g., first-time transfers). However, recent comprehensive reviews and individual participant data meta-analyses indicate that scratching may have been abandoned prematurely for complex cases. Targeted endometrial injury may offer modest but statistically significant benefits strictly for carefully selected patients with defined recurrent implantation failure (RIF)—particularly those identified with an immune under-activation profile. It should never replace structured diagnostic evaluations and must be applied via a biomarker-guided approach rather than as a universal add-on.

Which IVF add-ons are not routinely recommended after failed transfers?

Major international societies (ESHRE and ASRM) do not routinely recommend empirical immunomodulatory therapies (such as intravenous intralipids, high-dose systemic steroids, or IVIG), intrauterine PRP or G-CSF instillations, or routine inherited thrombophilia screening for isolated implantation failure.

Can chronic endometritis be tested and treated?

Chronic endometritis can be identified through an endometrial biopsy evaluated with CD138⁺ immunohistochemical staining. If persistent stromal plasma cell infiltration is confirmed, targeted oral antibiotic therapy may be prescribed, followed by clinical re-evaluation where appropriate.

When should a hydrosalpinx be evaluated before another embryo transfer?

Asymptomatic hydrosalpinges (fluid-filled Fallopian tubes) can leak fluid into the uterine cavity, which may impair the implantation environment. Ultrasound evaluation is recommended prior to subsequent transfers; if confirmed, surgical management (salpingectomy or tubal occlusion) is advised to restore optimal uterine conditions.

References

1. ESHRE Working Group on Recurrent Implantation Failure, Intra, L., et al. (2023). ESHRE good practice recommendations on recurrent implantation failure. Human Reproduction Open, 2023(3), hoad023.
2. Shoham, Z., et al. (2026). Re-evaluating endometrial injury for IVF: was a promising approach abandoned prematurely? A critical review. Reproductive BioMedicine Online, 52(6), 105371.
3. van Hoogenhuijze, N. E., et al. (2023). Endometrial scratching in women undergoing IVF/ICSI: an individual participant data meta-analysis. Human Reproduction Update, 29(6), 721-740.
4. Ledee, N., et al. (2020). Endometrial immune profiling: a method to design personalized care in assisted reproductive medicine. Frontiers in Immunology, 11:1032.
5. Practice Committee of the American Society for Reproductive Medicine (ASRM). (2020). Clinical management of mosaic results from preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion. Fertility and Sterility, 114(2), 246–254.
6. Practice Committee of the American Society for Reproductive Medicine (ASRM). (2021). The role of immunotherapy in in vitro fertilization: a committee opinion. Fertility and Sterility, 116(5), 1251–1262.
7. Cimadomo, D., et al. (2021). Clinical outcomes of euploid blastocyst transfers: a systematic review and meta-analysis. Human Reproduction Update, 27(4), 715–732.
8. Zegers-Hochschild, F., et al. (2017). The International Glossary on Infertility and Fertility Care, 2017. Human Reproduction, 32(9), 1786–1801.
9. Esteves SC, Humaidan P. Sperm DNA fragmentation: how to test, when to test, and what to do with abnormal results — a pragmatic mini-review for clinical practice. Hum Reprod. 2026 Jul 1;41(7):1024-1039.

Disclaimer: This article is for general educational purposes only and does not constitute medical advice, formal diagnosis, or a treatment recommendation. Healthcare choices and clinical pathways must be determined in direct consultation with a licensed reproductive endocrinologist following a comprehensive, individualized medical assessment.

About the author

Dr Ewa Goncikowska, MD, PhD
Specialist in Gynaecological Endocrinology, Reproduction & Infertility